Arca
Skip to content
Tools
Tools

PKLR: Pyruvate kinase PKLR

Pyruvate kinase that catalyzes the conversion of phosphoenolpyruvate to pyruvate with the synthesis of ATP, and which plays a key role in glycolysis.

  • Drugs that act on it: 2
  • Approved: 1
  • In phases 1 to 3: 1
  • Sponsors: 2

Who is on it, and how far along

Every drug ChEMBL records acting on PKLR, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule 2

Approved1

  • Mitapivat

Phase 30

    Phase 21

    • Etavopivat

    Phase 10

      The landscape

      Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials.
      MitapivatApprovedAgios PharmaceuticalsSmall moleculeActivatorPyruvate kinase isozymes R/L activator14
      EtavopivatPhase 2Forma Therapeutics, Inc.Small moleculeActivatorPyruvate kinase isozymes R/L activator5

      Open trials

      The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 13 in all, from ClinicalTrials.gov.
      A Study to Investigate the Effect of Mitapivat on Transfusion Burden in Subjects With Sickle Cell Disease (SCD)MitapivatPhase 3RecruitingAgios Pharmaceuticals, Inc.Jun 18, 2026
      A Study to Investigate the Efficacy, Pharmacokinetics, and Safety of Mitapivat in Pediatric Participants With α- or β-Non-Transfusion-Dependent ThalassemiaMitapivatPhase 3RecruitingAgios Pharmaceuticals, Inc.Apr 8, 2026
      A Study to Investigate the Efficacy, Pharmacokinetics, and Safety of Mitapivat in Pediatric Participants With Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-TDT)MitapivatPhase 3RecruitingAgios Pharmaceuticals, Inc.Apr 2, 2026
      To Assess Safety of Mitapivat and Provide Proof of Concept of the Efficacy of the Drug in Patients With RBC Membranopathies or CDAII.MitapivatPhase 2Active, not recruitingUniversity Health Network, TorontoJul 8, 2025
      A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell DiseaseEtavopivatPhase 3RecruitingNovo Nordisk A/SSep 25, 2024
      A Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or ThalassaemiaEtavopivatPhase 3RecruitingNovo Nordisk A/SSep 24, 2024
      A Study to Evaluate the Pharmacokinetics and Safety of Etavopivat in Pediatric Patients With Sickle Cell DiseaseEtavopivatPhase 2RecruitingForma Therapeutics, Inc.Jan 10, 2024
      A Phase 2 Open-label Study to Evaluate the Activity of Etavopivat on Transcranial Doppler Velocities in Pediatric Patients With Sickle Cell Disease Who Are at Increased Risk for Primary StrokeEtavopivatPhase 2RecruitingForma Therapeutics, Inc.Jul 20, 2023
      Safety and Efficacy of Mitapivat Sulfate in Adult Patients With Erythrocyte MembranopathiesMitapivatPhase 2Active, not recruitingEuroBloodNet AssociationJul 7, 2023
      A Study to Provide Access to Mitapivat for Participants Who Previously Participated in an Agios-Sponsored Mitapivat StudyMitapivatPhase 4Enrolling by invitationAgios Pharmaceuticals, Inc.Mar 21, 2023
      Investigating the Mechanistic Effects of Mitapivat in Subjects With Sickle Cell DiseaseMitapivat—Active, not recruitingNational Heart, Lung, and Blood Institute (NHLBI)Jan 9, 2023
      A Study to Evaluate the Efficacy and Safety of Mitapivat in Pediatric Participants With Pyruvate Kinase Deficiency (PKD) Who Are Not Regularly Transfused, Followed by a 5-Year Extension PeriodMitapivatPhase 3Active, not recruitingAgios Pharmaceuticals, Inc.Jan 3, 2022
      A Study of Etavopivat in Adults and Adolescents With Sickle Cell Disease (HIBISCUS)EtavopivatPhase 3Active, not recruitingForma Therapeutics, Inc.Nov 12, 2020

      Diseases most associated with it

      Open Targets association score, 0 to 1; all associations
      Pyruvate kinase deficiency of red cells
      0.86
      Pyruvate kinase hyperactivity
      0.65
      Gout
      0.53
      Abnormality of the skeletal system
      0.52
      Hereditary disease
      0.47
      Congenital anemia
      0.42
      Familial hemolytic anemia
      0.38
      Hemolytic anemia
      0.37
      Postinflammatory pulmonary fibrosis
      0.36

      Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL1075126, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-18. Gene name, function (UniProt P30613, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

      Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.